Sensitive Estrogen Detection Method Developed
|
By LabMedica International staff writers Posted on 13 Jan 2015 |

Image: The liquid chromatography–mass spectrometry LCMS-8050 triple quadrupole mass spectrometer (Photo courtesy of Shimadzu Corporation).
The hormone estrogen plays an important role in the human body and has been linked to everything from tumor growth to neuron loss during Alzheimer's disease, but detecting very small amounts of it in blood and other biological fluids can be difficult, especially in the limited amounts available in laboratory studies.
A new method for detecting trace amounts of estrogen has been developed that uses liquid chromatography-mass spectrometry (LC-MS) and tandem mass spectrometry (LC-MS/MS) which remains the most sensitive and specific technique for both quantitative and qualitative analysis of small molecules in biological samples.
Scientists at the University of Texas (Arlington, TX, USA) developed a method for ultra-trace determination of estrogens in human serum using a combination of charged bulk derivatization and weak cation exchange (WCX) RAM-based trap-and-elute LC–MS/MS. The LC system was equipped with four pumps (Pump A/B: LC-30AD, Pump C/D: LC-20AD XR), a SIL-30AC AS, and a CTO-30A column oven containing a 2-position six-port switching valve. The analyses have been performed with a prototype WCX RAM trap column (Shimadzu Corporation; Kyoto, Japan). The LC–MS/MS analysis was performed on a Shimadzu LCMS-8050 triple quadrupole mass spectrometer.
Mass spectrometry and chromatography are ways to separate, identify, and quantify molecules in a complex mixture. The process involving liquid chromatography-electrospray ionization-tandem mass spectrometry relies on a vital step called charge derivatization or using a permanently charged reagent to selectively trap the estrogens and isolate them from the lipids and proteins that could interfere with estrogen detection. The limits of detection (LODs) in the study were found to be 3 pg/mL for estriol, 7 pg/mL for estrone and 17α-estradiol, and 5 pg/mL for 17β-estradiol. The new method can be accomplished in less than 25 minutes, including sample preparation and was a sensitive and efficient method for detecting trace amounts at less than 10 parts per trillion in a 100 mL sample.
Jose A. Barrera, PhD, director of the Shimadzu Institute and a coauthor of the study, said, “This new method pushes the detection limit for estrogens to a level that is applicable to research, human health, medicine, and environmental analysis. Its being instituted as a routine service means that all scientists now have the capability to more closely relate research model findings to human health and physiology.” The study was published on November 27, 2014, in the journal Analytica Chimica Acta.
Related Links:
University of Texas
Shimadzu Corporation
A new method for detecting trace amounts of estrogen has been developed that uses liquid chromatography-mass spectrometry (LC-MS) and tandem mass spectrometry (LC-MS/MS) which remains the most sensitive and specific technique for both quantitative and qualitative analysis of small molecules in biological samples.
Scientists at the University of Texas (Arlington, TX, USA) developed a method for ultra-trace determination of estrogens in human serum using a combination of charged bulk derivatization and weak cation exchange (WCX) RAM-based trap-and-elute LC–MS/MS. The LC system was equipped with four pumps (Pump A/B: LC-30AD, Pump C/D: LC-20AD XR), a SIL-30AC AS, and a CTO-30A column oven containing a 2-position six-port switching valve. The analyses have been performed with a prototype WCX RAM trap column (Shimadzu Corporation; Kyoto, Japan). The LC–MS/MS analysis was performed on a Shimadzu LCMS-8050 triple quadrupole mass spectrometer.
Mass spectrometry and chromatography are ways to separate, identify, and quantify molecules in a complex mixture. The process involving liquid chromatography-electrospray ionization-tandem mass spectrometry relies on a vital step called charge derivatization or using a permanently charged reagent to selectively trap the estrogens and isolate them from the lipids and proteins that could interfere with estrogen detection. The limits of detection (LODs) in the study were found to be 3 pg/mL for estriol, 7 pg/mL for estrone and 17α-estradiol, and 5 pg/mL for 17β-estradiol. The new method can be accomplished in less than 25 minutes, including sample preparation and was a sensitive and efficient method for detecting trace amounts at less than 10 parts per trillion in a 100 mL sample.
Jose A. Barrera, PhD, director of the Shimadzu Institute and a coauthor of the study, said, “This new method pushes the detection limit for estrogens to a level that is applicable to research, human health, medicine, and environmental analysis. Its being instituted as a routine service means that all scientists now have the capability to more closely relate research model findings to human health and physiology.” The study was published on November 27, 2014, in the journal Analytica Chimica Acta.
Related Links:
University of Texas
Shimadzu Corporation
Latest Technology News
- Robotic Technology Unveiled for Automated Diagnostic Blood Draws
- ADLM Launches First-of-Its-Kind Data Science Program for Laboratory Medicine Professionals
- Aptamer Biosensor Technology to Transform Virus Detection
- AI Models Could Predict Pre-Eclampsia and Anemia Earlier Using Routine Blood Tests
- AI-Generated Sensors Open New Paths for Early Cancer Detection
- Pioneering Blood Test Detects Lung Cancer Using Infrared Imaging
- AI Predicts Colorectal Cancer Survival Using Clinical and Molecular Features
- Diagnostic Chip Monitors Chemotherapy Effectiveness for Brain Cancer
- Machine Learning Models Diagnose ALS Earlier Through Blood Biomarkers
- Artificial Intelligence Model Could Accelerate Rare Disease Diagnosis
Channels
Molecular Diagnostics
view channel
Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test
Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more
Blood Test Detects Early-Stage Cancers by Measuring Epigenetic Instability
Early-stage cancers are notoriously difficult to detect because molecular changes are subtle and often missed by existing screening tools. Many liquid biopsies rely on measuring absolute DNA methylation... Read more
“Lab-On-A-Disc” Device Paves Way for More Automated Liquid Biopsies
Extracellular vesicles (EVs) are tiny particles released by cells into the bloodstream that carry molecular information about a cell’s condition, including whether it is cancerous. However, EVs are highly... Read more
Blood Test Identifies Inflammatory Breast Cancer Patients at Increased Risk of Brain Metastasis
Brain metastasis is a frequent and devastating complication in patients with inflammatory breast cancer, an aggressive subtype with limited treatment options. Despite its high incidence, the biological... Read moreHematology
view channel
New Guidelines Aim to Improve AL Amyloidosis Diagnosis
Light chain (AL) amyloidosis is a rare, life-threatening bone marrow disorder in which abnormal amyloid proteins accumulate in organs. Approximately 3,260 people in the United States are diagnosed... Read more
Fast and Easy Test Could Revolutionize Blood Transfusions
Blood transfusions are a cornerstone of modern medicine, yet red blood cells can deteriorate quietly while sitting in cold storage for weeks. Although blood units have a fixed expiration date, cells from... Read more
Automated Hemostasis System Helps Labs of All Sizes Optimize Workflow
High-volume hemostasis sections must sustain rapid turnaround while managing reruns and reflex testing. Manual tube handling and preanalytical checks can strain staff time and increase opportunities for error.... Read more
High-Sensitivity Blood Test Improves Assessment of Clotting Risk in Heart Disease Patients
Blood clotting is essential for preventing bleeding, but even small imbalances can lead to serious conditions such as thrombosis or dangerous hemorrhage. In cardiovascular disease, clinicians often struggle... Read moreImmunology
view channelBlood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug
Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more
Whole-Genome Sequencing Approach Identifies Cancer Patients Benefitting From PARP-Inhibitor Treatment
Targeted cancer therapies such as PARP inhibitors can be highly effective, but only for patients whose tumors carry specific DNA repair defects. Identifying these patients accurately remains challenging,... Read more
Ultrasensitive Liquid Biopsy Demonstrates Efficacy in Predicting Immunotherapy Response
Immunotherapy has transformed cancer treatment, but only a small proportion of patients experience lasting benefit, with response rates often remaining between 10% and 20%. Clinicians currently lack reliable... Read moreMicrobiology
view channel
Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease
Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read moreAI-Powered Platform Enables Rapid Detection of Drug-Resistant C. Auris Pathogens
Infections caused by the pathogenic yeast Candida auris pose a significant threat to hospitalized patients, particularly those with weakened immune systems or those who have invasive medical devices.... Read morePathology
view channel
Engineered Yeast Cells Enable Rapid Testing of Cancer Immunotherapy
Developing new cancer immunotherapies is a slow, costly, and high-risk process, particularly for CAR T cell treatments that must precisely recognize cancer-specific antigens. Small differences in tumor... Read more
First-Of-Its-Kind Test Identifies Autism Risk at Birth
Autism spectrum disorder is treatable, and extensive research shows that early intervention can significantly improve cognitive, social, and behavioral outcomes. Yet in the United States, the average age... Read moreTechnology
view channel
Robotic Technology Unveiled for Automated Diagnostic Blood Draws
Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more
ADLM Launches First-of-Its-Kind Data Science Program for Laboratory Medicine Professionals
Clinical laboratories generate billions of test results each year, creating a treasure trove of data with the potential to support more personalized testing, improve operational efficiency, and enhance patient care.... Read moreAptamer Biosensor Technology to Transform Virus Detection
Rapid and reliable virus detection is essential for controlling outbreaks, from seasonal influenza to global pandemics such as COVID-19. Conventional diagnostic methods, including cell culture, antigen... Read more
AI Models Could Predict Pre-Eclampsia and Anemia Earlier Using Routine Blood Tests
Pre-eclampsia and anemia are major contributors to maternal and child mortality worldwide, together accounting for more than half a million deaths each year and leaving millions with long-term health complications.... Read moreIndustry
view channelNew Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing
Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
AI-Powered Cervical Cancer Test Set for Major Rollout in Latin America
Noul Co., a Korean company specializing in AI-based blood and cancer diagnostics, announced it will supply its intelligence (AI)-based miLab CER cervical cancer diagnostic solution to Mexico under a multi‑year... Read more
Diasorin and Fisher Scientific Enter into US Distribution Agreement for Molecular POC Platform
Diasorin (Saluggia, Italy) has entered into an exclusive distribution agreement with Fisher Scientific, part of Thermo Fisher Scientific (Waltham, MA, USA), for the LIAISON NES molecular point-of-care... Read more







 Analyzer.jpg)